Shilpa Medicare Q1 FY27 PAT up 115 percent on consolidated basis, revenue up 43 percent

Revenue Growth 20pctPat Growth 25pctResults RestatedExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+12.1%Reaction day

₹648.50

prior close

₹646.35

announcement price

In-mkt

timing

Nifty Microcap 250market+1.3%+10.8% vs market

Pharmaceuticals peers, median of 165sector-0.0%+12.1% vs sector

On the reaction day the stock moved 10.8 pts more than Nifty Microcap 250 and 12.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+3.2

15m

+5.3

30m

+11.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+12.1+1.3+10.8-0.0+12.1

Next day

+13.7+1.6+12.1+0.1+13.6

+16.9+1.7+15.2+0.3+16.5

+24.6+1.6+23.0+1.0+23.6

+26.5+1.5+25.1+1.2+25.4

+23.8+1.8+22.0+1.0+22.9

+27.0+2.1+24.9+0.5+26.5

15d

+33.2+3.2+30.0-0.0+33.2

+45.0+3.7+41.3+1.7+43.3

+58.8+1.1+57.6+1.0+57.8

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare Q1 FY27: Consolidated revenue rose about 43 percent YoY to Rs 465.78 crore and PAT jumped around 115 percent to Rs 100.88 crore (EPS Rs 5.16 vs Rs 2.40). Standalone PAT of Rs 64.92 crore was boosted by a one-time deferred tax reversal of about Rs 26.84 crore. Standalone revenue grew 14 percent. Board approved up to EUR 7 million investment in Spain-based Gate2Brain through wholly-owned subsidiary Shilpa Biocare. Prior Q1 FY26 figures restated for merger of Shilpa Therapeutics with the company. Final AGM set for September 11; dividend record date September 4, 2026.

Likely market impact

Strong quarter on consolidated basis; standalone PAT flattered by one-time deferred tax benefit. EUR 7 million strategic investment in Gate2Brain and restated prior-year numbers are key items for investors to note.